Peer-supporting for Teenagers With Cystic Fibrosis in the Transition of Care From Paediatric to Adult Services

NCT05795673 | Not Yet Recruiting

• 1 other identifier: 69HCL21_1096
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 4

Brief Summary

In patients with cystic fibrosis, a deterioration in lung function around age 18, the age of transfer from pediatrics to adult care services, has been observed. Transfer is only one step in a transition process from pediatric to adult care taking place from age 12 to 24. Adolescence is a period of identity construction during which the disease alters self-image and self-esteem, and a period of empowerment in the management of the disease involving a re-appropriation of it. During this period, coping strategies and psychosocial skills are important to face all the issues that the adolescent encounters. Interventions for youth with chronic illnesses rarely incorporate this dimension. Peer support or peer-mentoring is one avenue for developing these coping skills. Peer support encompasses mutual support between people who are coping or have coped with similar challenging life experiences. Individuals with similar experiences would represent more credible role models to stimulate positive change in their peers. The function of peer support are to provide emotional, experiential, informational support.The effect of peer support improves social integration, coping skills, sense of self-efficacy of the peers being helped. Promotion of healthy youth behaviors by youth is the most widely evaluated youth engagement strategy in the community health sector. Peer-assisted devices have been tested to improve medication adherence and health status with youth with juvenile arthritis, asthma, and liver transplant recipients. By sharing their experience of a successful transition, young adults with cystic fibrosis may be able to help their adolescent peers better understand this transition. Our hypothesis is that implementing peer support with adolescents with cystic fibrosis improves their sense of self-efficacy, a dimension of coping skills.To our knowledge, there are no research studies on peer support in cystic fibrosis in France or abroad. Patients are recognized as partners capable of sharing their experiential knowledge with patients with a similar disease. But this raises questions about the recruitment, supervision, preparation for peer-help and the role of these patients; about the effects of their involvement for themselves (valorization, anxiety) and for their peers (re-assurance, feeling of personal effectiveness). This justifies conducting an exploratory study to assess the feasibility of a peer-support intervention for youth with cystic fibrosis.

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis; Peer helping; Transition

Outcome Measures

Primary Outcomes (2)

• Change from baseline Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 6 months

  Change in Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 6 months. The CFQ-R includes 34 cystic fibrosis-specific quality of life items, scored on a 4-modality scale, and exploring 9 dimensions including perceived health, burden of treatment, self-image (and body image in particular), emotional state, and social interaction that are particularly impacted by the transition period. The responses allow us to establish a score on a scale of 0 to 100, the higher the score the better the quality of life.

  Baseline ; at 6 months

• Change from baseline Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 3 months

  Change in Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 3 months. The CFQ-R includes 34 cystic fibrosis-specific quality of life items, scored on a 4-modality scale, and exploring 9 dimensions including perceived health, burden of treatment, self-image (and body image in particular), emotional state, and social interaction that are particularly impacted by the transition period. The responses allow us to establish a score on a scale of 0 to 100, the higher the score the better the quality of life.

  Baseline ; at 3 months

Secondary Outcomes (11)

• Effect of peer support model during pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents and non-sponsored adolescents) on their sense of self-efficacy

  Measurement at inclusion, 3 months and 6 months

• Effect of peer support model during pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents, included in post period, and non-sponsored adolescents, included in pre period) on management and therapeutic adherence

  Measurement at inclusion, 3 months and 6 months

• Effect of peer support model during the pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents, included in the post period, and non-sponsored adolescents, included in the pre period) on sense of social integration.

  Measurement at inclusion, 3 months and 6 months

• Fidelity of peer-assistance process in relation to what was planned (criteria collected in the "after" period only).

  From inclusion to the end of pair-aidance, up to 8 months

• Experience (Experience, Satisfaction, Acceptability) of peer support among sponsored adolescents, sponsors, parents and accompanying professionals by individual interviews 1 to 2 months after the end of peer support (collected in the "after" period).

  From inclusion to the end of pair-aidance, up to 8 months

Study Arms (2)

Group Peer support

OTHER

Intervention of mentor to provide peer support

Other: Peer support program (intervention phase)

Group Control

NO INTERVENTION

Usual practices of accompaniment of the pediatric-adult transition

Interventions

Peer support program (intervention phase) OTHER

Implementation and Evaluation: Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation. The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone. The mentor will know the themes that the teenager would like to address in the context of peer support. The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints.

Group Peer support

Eligibility Criteria

• Age: 15 Years - 24 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• patient affected by cystic fibrosis
• patient able to understand and read French
• patient from 15 to 19 years , in a process of transition on paediatric care to adult care
• with a follow-up on a paediatric Cystic Fibrosis Centers Competences (CRCM)
• did not participate in the Phase 1 co-construction workgroup
• affiliated to the social security system
• having agreed to participate and signed the consent for an adult patient, or legal guardian having agreed to participate and signed the consent for a minor patient

You may not qualify if:

• patient with transplant
• patient with cystic fibrosis transmembrane regulator-related disorders (CFTR RD) or Screen Positive Inconclusive Diagnosis (SPID) Cystic Fibrosis
• patient with a curator, tutor or under the protection of a conservator
• pregnant or breastfeeding patient
• Concerning the mentor/peer-supporter (post period):
• affected cystic fibrosis
• able to understand and read French
• young adult, 19 to 24 years old
• with a follow-up on the adult CRCM (transition completed)
• affiliated to the social security system
• have agreed to participate and signed the consent form
• did not participate in the Phase 1 co-construction workgroup
• patient with transplant
• patient with CFTR RD or SPID Cystic Fibrosis
• patient with a curator, tutor or under the protection of a conservator

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (4)

CRCM Lyon pédiatrie - Hôpital Femme Mère Enfant, Hospices Civils de Lyon

Bron, 69500, France

Location

CRCM Grenoble adulte - Hôpital Albert Michallon

Grenoble, 38000, France

Location

CRCM Grenoble pédiatrie - Hôpital Albert Michallon

Grenoble, 38000, France

Location

CRCM Lyon adulte - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon

Pierre-Bénite, 69495, France

Location

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Officials

• Quitterie REYNAUD, MD

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Stéphanie POUPON-BOURDY

CONTACT

0472115416; stephanie.poupon-bourdy@chu-lyon.fr

Sophie HOMMEY

CONTACT

0472115760; sophie.hommey@chu-lyon.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Prospective quasi-experimental before-and-after multicenter study

Study Record Dates

• First Submitted: February 2, 2023
• First Posted: April 3, 2023
• Study Start: September 1, 2023
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: August 8, 2023

Record last verified: 2023-08

Locations

FR (4)